How to buy Spero Therapeutics stock (SPRO)

Spero Therapeutics is a biotechnology business based in the US. Spero Therapeutics shares (SPRO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.96 – a decrease of 10.74% over the previous week. Spero Therapeutics employs 46 staff and has a trailing 12-month revenue of around $118.5 million.

Our top picks for where to buy Spero Therapeutics stock

Buy Spero Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Spero Therapeutics stock price (NASDAQ: SPRO)

Use our graph to track the performance of SPRO stocks over time.

Spero Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.96
52-week range	$0.99 - $1.89
50-day moving average more info button	$1.22
200-day moving average more info button	$1.40
Wall St. target price	$5.00
PE ratio more info button	12.435
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.08

Is it a good time to buy Spero Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Spero Therapeutics price performance over time

Historical closes compared with the close of $0.9551 from 2024-12-20

1 week (2024-12-13)	-10.74%
1 month (2024-11-22)	-17.66%
3 months (2024-09-20)	-28.19%
6 months (2024-06-21)	-30.28%

1 year (2023-12-22)	-29.25%
2 years (2022-12-22)	-39.93%
3 years (2021-12-22)	13.7
5 years (2019-12-20)	10.82

Is Spero Therapeutics stock undervalued or overvalued?

Valuing Spero Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Spero Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Spero Therapeutics's P/E ratio

Spero Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Spero Therapeutics shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Spero Therapeutics's EBITDA

Spero Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21 million.

The EBITDA is a measure of a Spero Therapeutics's overall financial performance and is widely used to measure a its profitability.

Spero Therapeutics financials

Revenue TTM	$118.5 million
Gross profit TTM	$-42,107,000
Return on assets TTM	10.48%
Return on equity TTM	25.81%
Profit margin	14.74%
Book value	$2.02
Market Capitalization more info button	$54.2 million

TTM: trailing 12 months

Spero Therapeutics share dividends

We're not expecting Spero Therapeutics to pay a dividend over the next 12 months.

Spero Therapeutics share price volatility

Over the last 12 months, Spero Therapeutics's shares have ranged in value from as little as $0.99 up to $1.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Spero Therapeutics's is 0.631. This would suggest that Spero Therapeutics's shares are less volatile than average (for this exchange).

Spero Therapeutics overview

Spero Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co. , Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc.

Frequently asked questions

What percentage of Spero Therapeutics is owned by insiders or institutions?
Currently 20.133% of Spero Therapeutics shares are held by insiders and 23.047% by institutions. How many people work for Spero Therapeutics?
Latest data suggests 46 work at Spero Therapeutics. When does the fiscal year end for Spero Therapeutics?
Spero Therapeutics's fiscal year ends in December. Where is Spero Therapeutics based?
Spero Therapeutics's address is: 675 Massachusetts Avenue, Cambridge, MA, United States, 02139 What is Spero Therapeutics's ISIN number?
Spero Therapeutics's international securities identification number is: US84833T1034 What is Spero Therapeutics's CUSIP number?
Spero Therapeutics's Committee on Uniform Securities Identification Procedures number is: 84833T103